Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 12, Issue 7, Pages 877-879Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.12.71
Keywords
ALK inhibitors; anti-EGFR antibodies; BATTLE trial; bioinformatics; biomarkers; biopsy-driven trials; BRAF inhibitors; drug resistance; I-SPY trial; personalized medicine; tumor heterogeneity
Categories
Ask authors/readers for more resources
Third Quebec Conference on Therapeutic Resistance in Cancer Montreal, QC, Canada, 15-16 March 2012 Despite advances in personalized medicine and targeted therapies, therapeutic resistance remains a persistent dilemma encountered by clinicians, scientists and patients. In this article we summarize the highlights of the third Quebec Conference on Therapeutic Resistance in Cancer. This unique meeting provided researchers and clinicians with insights into: intrinsic and acquired resistance; tumor heterogeneity; complexities of biomarker-driven trials; challenges of 'omics data analysis; and models of clinical applications of personalized medicine. Emphasized throughout the conference was the importance of collaborations between industry and academia, and between basic researchers and clinicians so that therapeutic resistance can be studied where it matters most, in patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available